

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

NCI-H727

RRID:CVCL_1584

Type: Cell Line

Proper Citation

RRID:CVCL_1584

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1584

Proper Citation: RRID:CVCL_1584

Description: Cell line NCI-H727 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung carcinoid tumor

Defining Citation: [PMID:1311061](#), [PMID:1563005](#), [PMID:8626706](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:12068308](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:22538498](#), [PMID:22929519](#), [PMID:23119007](#), [PMID:24135919](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26087898](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H727

Synonyms: H727, H-727, NCIH727

Cross References: BTO:BTO_0005915, CLO:CLO_0008111, EFO:EFO_0006695, CLDB:cl3659, CLDB:cl3660, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5815,

BioSample:SAMN03472579, BioSample:SAMN10988551, cancercellines:CVCL_1584, Cell_Model_Passport:SIDM01119, ChEMBL-Cells:ChEMBL3308393, ChEMBL-Targets:ChEMBL1075545, Cosmic:722049, Cosmic:724855, Cosmic:877412, Cosmic:897515, Cosmic:980994, Cosmic:1006542, Cosmic:1032466, Cosmic:1152507, Cosmic:1239952, Cosmic:1802311, Cosmic:1879413, Cosmic:1998332, Cosmic:2125257, Cosmic:2433547, Cosmic-CLP:724855, DepMap:ACH-000775, ECACC:94060303, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10735-110B6, GDSC:724855, GEO:GSM385523, GEO:GSM385534, GEO:GSM600372, GEO:GSM784194, GEO:GSM794299, GEO:GSM827523, GEO:GSM830114, GEO:GSM887444, GEO:GSM888524, GEO:GSM1374760, GEO:GSM1670261, IARC_TP53:527, IARC_TP53:28250, ICLC:HTL97001, IGRhCellID:NCI-H727%20GEO, KCLB:90727, LiGeA:CCLE_211, LINCS_LDP:LCL-1153, PharmacDB:NCIH727_1133_2019, PRIDE:PXD030304, Progenetix:CVCL_1584, PubChem_Cell_line:CVCL_1584, Ubigen:YC-C129, Wikidata:Q54908114

ID: CVCL_1584

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260913T004957+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H727.

No alerts have been found for NCI-H727.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. Cancer discovery, 16(5), 895.

Pan Y, et al. (2025) Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer. iScience, 28(2), 111864.

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. Cancer cell.

Conn BP, et al. (2025) Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell reports methods, 5(5), 101049.

Sun F, et al. (2024) Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. *eLife*, 12.

Sealover NE, et al. (2024) In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies. *iScience*, 27(1), 108711.

Grant CE, et al. (2024) DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC. *Molecular oncology*, 18(6), 1631.

Soldevilla B, et al. (2023) MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms. *Molecular oncology*, 17(4), 582.

Shonibare Z, et al. (2022) Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer. *Cell reports*, 40(4), 111066.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. *Cell chemical biology*, 27(1), 105.